This report presents the results of a study that dealt specifically with effective communication around the benefit and risk balance of vaccination people’s risk perceptions around vaccines and diseases, and approaches to enhancing communication about the safety and effectiveness of vaccines.
ECDC, DG SANTE and EFSA, supported by a consortium composed of Epiconcept and Integrated Quality Laboratory Services (IQLS), jointly carried out a country visit to Kosovo* from 9 to 13 October 2023, which is part of ECDC’s accession support activities to contribute to the advancement of a One Health approach against antimicrobial resistance (AMR) in the Western Balkans.
This report contains genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 August 2023 until 31 January 2024.
The 2022–2023 ECDC PPS was the third EU-wide point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals.
Diverse groups of experts helped assess the relationships between drivers on an extended time-horizon: assessing either no connection, some connection or a strong connection between two drivers along any of their possible future trajectories.
This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
This report presents surveillance data on Clostridioides (Clostridium) difficile infection (CDI) in acute care hospitals in European Union/European Economic Area (EU/EEA) countries, the UK, and Serbia.
The decline in the reported number of new transmissions of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections across European Union (EU) and European Economic Area (EEA) countries has continued.
In this report, we provide an overview of the data reported by countries in the EU and EEA in 2023 to describe progress towards the 2025 interim targets for hepatitis elimination as outlined in the WHO European Region Action Plan 2022–2030.